Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597884 | 0.77 | CYP2D6 (0.39) | ALDH1A1PRMT3GAARXFP1HDAC4 | |
| SCHEMBL5945865 | 0.77 | KDM4E (0.40) | ALDH1A1PRMT3GAARXFP1HDAC4 | |
| SCHEMBL9156485 | 0.74 | — | — | |
| SCHEMBL13853544 | 0.73 | PRMT3 (0.39) | ALDH1A1PRMT3GAARXFP1HDAC4 | |
| SCHEMBL17447516 | 0.73 | MEN1 (0.46) | ALDH1A1PRMT3GAARXFP1HDAC4 | |
| SCHEMBL13627778 | 0.73 | EPHX1 (0.39) | ALDH1A1PRMT3GAARXFP1HDAC4 | |
| SCHEMBL10414888 | 0.73 | EGLN1 (0.31) | GAARXFP1 | |
| SCHEMBL11290372 | 0.73 | ALDH1A1 (0.35) | ALDH1A1PRMT3GAARXFP1LMNA | |
| SCHEMBL12530768 | 0.71 | ALDH1A1 (0.39) | ALDH1A1TDP1PRMT3GAARXFP1 | |
| SCHEMBL18854339 | 0.71 | PREP (0.36) | ALDH1A1PRMT3GAARXFP1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345899-B1 | N-substituted amides as NK1 receptor antagonists | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | claimed |
| US-7064136-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | claimed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | claimed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | claimed |
| US-20040058916-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | claimed |
| EP-1345899-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | claimed |
| WO-2002051807-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | claimed |
| EP-1137637-A1 | N-(2-PHENYL-4-PIPERIDINYLBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-10-04 | — | — | EP | claimed |
| WO-2000034243-A1 | N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | claimed |
| EP-1345899-B1 | N-substituted amides as NK1 receptor antagonists | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-7064136-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058916-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| WO-2002051807-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
| US-6403601-B1 | TREATMENT OF ASTHMA, ANXIETY, DEPRESSION, EMESIS, URINARY INCONTINENCE AND RELATED CONDITIONS. | ASTRAZENECA AB (SE) | 2002-06-11 | — | — | US | disclosed |
| EP-1137637-A1 | N-(2-PHENYL-4-PIPERIDINYLBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-10-04 | — | — | EP | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000034243-A1 | N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058916-A1 | Compounds | CYP11B2, CYP11B1, PCSK9 | ALDH1A1 816/4885TDP1 2473/4885PRMT3 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.